Thank you. That relates to the area that I was going to ask about. Also, thanks for the information. It's interesting information that I certainly wasn't aware of.
On the cost side, though, it seems to me that what your organizations are asking for is to extend patent protection, using the trade agreement to do it. Number one, have you looked at the cost side? We're informed by the generic industry that the additional costs of longer patents would increase the cost to our public health care system, in one way or another, to $2.6 billion or $2.8 billion. The pharmaceutical industry, on the other hand, disagrees with those numbers, and they talk about there being new investment, new drugs, and better results, so the generic drug figure doesn't have as much merit as it sounds like on the surface.
So number one, have you looked at the cost side? Also, do you see our health care system being better off as a result or more costly?